Nu.Q Vet Cancer Test
The Nu.Q Vet Cancer Test* detects 7 common canine cancers at an overall detection rate of 49.8%.1
Now you can include the Nu.Q Vet Cancer Test along with routine preventive care diagnostics.
The Nu.Q Vet Cancer Test detects 7 common canine cancers at an overall detection rate of 49.8%.†1
†At 97% specificity.
- Detects circulating nucleosomes released by cancer cells using capture ELISA
- Minimally invasive (2–5 mL LTT blood specimen) with results received within 1–4 days
- Comprehensive support from IDEXX throughout your patient’s cancer diagnosis and treatment
- Results in VetConnect PLUS for a holistic view of your patients’ health
IDEXX recommends screening at-risk dogs, including all dogs aged 7 or older and dogs of high-risk breeds aged 4 or older, particularly in the following breeds:
- Labrador retriever
- French bulldog
- Golden retriever
- German shepherd
- Beagle
- Rottweiler
- Boxer
- Pembroke Welsh corgi
- Great Dane
- Miniature schnauzer
- Siberian husky
- Bernese mountain dog
- Mastiff
- Irish wolfhound
- Flat-coated retriever
- Scottish wolfhound
Put our cancer portfolio to work.
We’ve developed a full suite of diagnostic tools for treatment, monitoring, management, and support for every stage of veterinary oncology.
Order your Nu.Q Vet Cancer Test
Nu.Q Vet Cancer Test (test code 8993)
For cancer, this may include one or more of the following: 3-view chest radiographs, ultrasonography, computed tomography, MRI, or endoscopy. Appropriate specimens should be collected for pathology testing to achieve a definitive cancer diagnosis.
* Nu.Q, Nucleosomics and Volition are trademarks of VolitionRx Limited and its subsidiaries. The Nu.Q Vet Cancer Test is supplied by Belgian Volition SRL.
Reference
- Wilson-Robles HM, Bygott T, Kelly TK, et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res. 2022;18(1):329. doi:10.1186/s12917-022-03429-8